title: Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: an exploratory study.
abstract: Alzheimer's disease (AD) is characterized by intraneuronal β-amyloid plaques and hyperphosphorylated tau, leading to neuronal cell death and progressive memory losses. This exploratory work investigates if dietary resveratrol, previously shown to have broad anti-aging effects and improve AD pathology in vivo, leads to neuroprotective changes in specific protein targets in the mouse brain. Both wild-type and APP/PS1 mice, a transgenic AD mouse model, received control AIN-93G diet or AIN-93G supplemented with resveratrol. Pathology parameters and AD risk were assessed via measurements on plaque burden, levels of phosphorylated glycogen synthase kinase 3-β (GSK3-β), tau, transthyretin and drebrin. Dietary resveratrol treatment did not decrease plaque burden in APP/PS1 mice. However, resveratrol-fed mice demonstrated increases in GSK3-β phosphorylation, a 3.8-fold increase in protein levels of transthyretin, and a 2.2-fold increase in drebrin. This study broadens our understanding of specific mechanisms and targets whereby resveratrol provides neuroprotection.
authors.affiliation: Division of Nutritional Sciences, Cornell University , Ithaca, NY , USA and.
authors.forename: Behzad
authors.initials: B
authors.lastname: Varamini
authors.forename: Angelos K
authors.initials: AK
authors.lastname: Sikalidis
authors.forename: Kathryn L
authors.initials: KL
authors.lastname: Bradford
mesh_terms: D000544:Alzheimer Disease / Q000178:diet therapy* / Q000378:metabolism / Q000473:pathology; D016564:Amyloid beta-Protein Precursor / Q000235:genetics / Q000378:metabolism; D000818:Animals; D054022:Cerebrum / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D019587:Dietary Supplements; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000071679:Glycogen Synthase Kinase 3 beta; D006801:Humans; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D050506:Mutant Chimeric Proteins / Q000378:metabolism; D009154:Mutation; D009419:Nerve Tissue Proteins / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D009474:Neurons / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D009479:Neuropeptides / Q000819:agonists / Q000378:metabolism; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010766:Phosphorylation; D011228:Prealbumin / Q000819:agonists / Q000378:metabolism; D053764:Presenilin-1 / Q000235:genetics / Q000378:metabolism; D011499:Protein Processing, Post-Translational; D011994:Recombinant Proteins / Q000378:metabolism; D000077185:Resveratrol; D013047:Specific Pathogen-Free Organisms; D013267:Stilbenes / Q000627:therapeutic use*
chemical_list: D016564:Amyloid beta-Protein Precursor; D050506:Mutant Chimeric Proteins; D009419:Nerve Tissue Proteins; D009479:Neuropeptides; D018696:Neuroprotective Agents; C508853:PSEN1 protein, human; D011228:Prealbumin; D053764:Presenilin-1; D011994:Recombinant Proteins; D013267:Stilbenes; C053386:drebrins; D000071679:Glycogen Synthase Kinase 3 beta; D038362:Glycogen Synthase Kinase 3; D000077185:Resveratrol